Curr Pharm Des. 2012;18(5):683-95. doi: 10.2174/138161212799315975.
The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/or European regulatory approvals. Lung delivery technologies, in regards to inhaled antibiotics for CF, are also reviewed.
在过去的三十年里，针对铜绿假单胞菌感染的吸入抗生素领域为囊性纤维化（CF）患者的健康、疾病管理和预期寿命做出了重大贡献。本文综述了 CF 吸入抗生素领域的一些最新临床进展，并简要描述了美国和/或欧洲监管批准的制剂和正在进行的开发。本文还回顾了 CF 吸入抗生素的肺部给药技术。
